Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 10/20 | 0.61 |
| ▸ | AKT1 | P31749 | 6/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | ILK | Q13418 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.39 |
| ▸ | PRKACA | P17612 | 2/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.39 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | PRKACB | P22694 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432987 | 0.83 | AKT2 (0.76) | AKT2AKT1ROCK2ILKPLK1 | |
| SCHEMBL15689115 | 0.83 | AKT2 (0.76) | AKT2AKT1ROCK2ILKPLK1 | |
| SCHEMBL3740850 | 0.80 | AKT2 (0.70) | AKT2AKT1ROCK2ILKACVR1 | |
| SCHEMBL3141719 | 0.78 | AKT2 (0.47) | AKT2AKT1ROCK2ILKACVR1 | |
| SCHEMBL2156408 | 0.78 | ILK (0.43) | AKT2AKT1ILKMAPK1 | |
| Hydrochloric Acid SCHEMBL28973063 | 0.77 | AKT2 (0.67) | AKT2AKT1ROCK2ILKACVR1 | |
| Benzene SCHEMBL28198087 | 0.76 | AKT2 (1.00) | AKT2AKT1ROCK2ILKPIM1 | |
| SCHEMBL82741 | 0.76 | AKT2 (1.00) | AKT2AKT1ROCK2ILKPIM1 | |
| SCHEMBL294336 | 0.75 | AKT2 (0.59) | AKT2AKT1ROCK2ILKMAPK1 | |
| SCHEMBL16872766 | 0.74 | AKT2 (0.95) | AKT2AKT1ROCK2ILKPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | PTC THERAPEUTICS INC (US) | 2023-06-29 | — | — | US | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| US-10125144-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2018-11-13 | — | — | US | claimed |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | SELVITA S.A. (PL) | 2018-09-20 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| EP-3356331-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | Selvita S.A. (PL) | 2018-08-08 | — | — | EP | claimed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | claimed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | claimed |
| CN-1741994-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP (US) | 2006-03-01 | — | — | CN | claimed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | claimed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | claimed |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LIMITED (GB) | 2005-07-07 | — | — | US | claimed |
| CN-1606443-A | Substituted diketopiperazines as oxytocin antagonists | GLAXO GROUP LTD (GB) | 2005-04-13 | — | — | CN | claimed |
| WO-2005000311-A1 | SUBSTITUTED DIKETOPIPERAZINES FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | WO | claimed |
| EP-1458393-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-09-22 | — | — | EP | claimed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | claimed |
| WO-2003053443-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-07-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | AKT2 1682/4885AKT1 1384/4885ROCK2 643/4885 |
| US-20050148572-A1 | Substituted diketopiperazines as oxytocin antagonists | OXTR, AVPR2, AVPR1B | AKT2 4538/4885AKT1 4800/4885ROCK2 4300/4885 |
| US-10125144-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | AKT2 11/4885AKT1 22/4885ROCK2 1/4885 |
| US-20180265467-A1 | PYRAZOLIDINE DERIVATIVES AND RELATED COMPOUNDS | LDHB, LDHA, PDK1 | AKT2 2820/4885AKT1 3463/4885ROCK2 4081/4885 |
| US-20230201200-A1 | Methods for Treating Huntington’s Disease | HTT, HYPK, HDAC6 | AKT2 3450/4885AKT1 3356/4885ROCK2 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.